TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Aflibercept Biosimilars Market, Global Outlook and Forecast 2022-2028

Aflibercept Biosimilars Market, Global Outlook and Forecast 2022-2028

  • Category:Life Sciences
  • Published on : 10 August 2022
  • Pages :126
  • Formats:
  • Report Code:SMR-7263469
OfferClick for best price

Best Price: $2600

Aflibercept Biosimilars Market Size, Share 2022


Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It is an inhibitor of vascular endothelial growth factor (VEGF).

This report contains market size and forecasts of Aflibercept Biosimilars in global, including the following market information:

Global Aflibercept Biosimilars Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Aflibercept Biosimilars Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Aflibercept Biosimilars companies in 2021 (%)

The global Aflibercept Biosimilars market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Intravitreal Injection Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Aflibercept Biosimilars include Regeneron, Sanofi, Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Aflibercept Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Aflibercept Biosimilars Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Aflibercept Biosimilars Market Segment Percentages, by Type, 2021 (%)

Intravitreal Injection

Intravenous Injection

Global Aflibercept Biosimilars Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Aflibercept Biosimilars Market Segment Percentages, by Application, 2021 (%)

Wet Macular Degeneration

Metastatic Colorectal Cancer

Global Aflibercept Biosimilars Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Aflibercept Biosimilars Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Aflibercept Biosimilars revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Aflibercept Biosimilars revenues share in global market, 2021 (%)

Key companies Aflibercept Biosimilars sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Aflibercept Biosimilars sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Regeneron

Sanofi

Novartis

Genentech

Roche

Pfizer

Sartorius

Eli Lilly

Bayer

Amgen

PlantForm

PharmaPraxis

Samsung Bioepis

Centus

Cadila Pharmaceuticals

Dr Reddy's

Aurobindo Pharma

Biocad

MAbxience

Hetero

Biocon

Kirin Biologics

Mylan

BeiGene

Innovent

Qilu Pharmaceutical

Hengrui Pharmaceuticals

Hisun Pharmaceutical

TOT BIOPHARM

Report Attributes Report Details
Report Title Aflibercept Biosimilars Market, Global Outlook and Forecast 2022-2028
Historical Year 2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year 2021
Forecast Year 2029
Number of Pages 126 Pages
Customization Available Yes, the report can be customized as per your need.

TABLE OF CONTENTS

1 Introduction to Research & Analysis Reports
1.1 Aflibercept Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Aflibercept Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Aflibercept Biosimilars Overall Market Size
2.1 Global Aflibercept Biosimilars Market Size: 2021 VS 2028
2.2 Global Aflibercept Biosimilars Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Aflibercept Biosimilars Sales: 2017-2028
3 Company Landscape
3.1 Top Aflibercept Biosimilars Players in Global Market
3.2 Top Global Aflibercept Biosimilars Companies Ranked by Revenue
3.3 Global Aflibercept Biosimilars Revenue by Companies
3.4 Global Aflibercept Biosimilars Sales by Companies
3.5 Global Aflibercept Biosimilars Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Aflibercept Biosimilars Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Aflibercept Biosimilars Product Type
3.8 Tier 1, Tier 2 and Tier 3 Aflibercept Biosimilars Players in Global Market
3.8.1 List of Global Tier 1 Aflibercept Biosimilars Companies
3.8.2 List of Global Tier 2 and Tier 3 Aflibercept Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Aflibercept Biosimilars Market Size Markets, 2021 & 2028
4.1.2 Intravitreal Injection
4.1.3 Intravenous Injection
4.2 By Type - Global Aflibercept Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Aflibercept Biosimilars Revenue, 2017-2022
4.2.2 By Type - Global Aflibercept Biosimilars Revenue, 2023-2028
4.2.3 By Type - Global Aflibercept Biosimilars Revenue Market Share, 2017-2028
4.3 By Type - Global Aflibercept Biosimilars Sales & Forecasts
4.3.1 By Type - Global Aflibercept Biosimilars Sales, 2017-2022
4.3.2 By Type - Global Aflibercept Biosimilars Sales, 2023-2028
4.3.3 By Type - Global Aflibercept Biosimilars Sales Market Share, 2017-2028
4.4 By Type - Global Aflibercept Biosimilars Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Aflibercept Biosimilars Market Size, 2021 & 2028
5.1.2 Wet Macular Degeneration
5.1.3 Metastatic Colorectal Cancer
5.2 By Application - Global Aflibercept Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Aflibercept Biosimilars Revenue, 2017-2022
5.2.2 By Application - Global Aflibercept Biosimilars Revenue, 2023-2028
5.2.3 By Application - Global Aflibercept Biosimilars Revenue Market Share, 2017-2028
5.3 By Application - Global Aflibercept Biosimilars Sales & Forecasts
5.3.1 By Application - Global Aflibercept Biosimilars Sales, 2017-2022
5.3.2 By Application - Global Aflibercept Biosimilars Sales, 2023-2028
5.3.3 By Application - Global Aflibercept Biosimilars Sales Market Share, 2017-2028
5.4 By Application - Global Aflibercept Biosimilars Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Aflibercept Biosimilars Market Size, 2021 & 2028
6.2 By Region - Global Aflibercept Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Aflibercept Biosimilars Revenue, 2017-2022
6.2.2 By Region - Global Aflibercept Biosimilars Revenue, 2023-2028
6.2.3 By Region - Global Aflibercept Biosimilars Revenue Market Share, 2017-2028
6.3 By Region - Global Aflibercept Biosimilars Sales & Forecasts
6.3.1 By Region - Global Aflibercept Biosimilars Sales, 2017-2022
6.3.2 By Region - Global Aflibercept Biosimilars Sales, 2023-2028
6.3.3 By Region - Global Aflibercept Biosimilars Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Aflibercept Biosimilars Revenue, 2017-2028
6.4.2 By Country - North America Aflibercept Biosimilars Sales, 2017-2028
6.4.3 US Aflibercept Biosimilars Market Size, 2017-2028
6.4.4 Canada Aflibercept Biosimilars Market Size, 2017-2028
6.4.5 Mexico Aflibercept Biosimilars Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Aflibercept Biosimilars Revenue, 2017-2028
6.5.2 By Country - Europe Aflibercept Biosimilars Sales, 2017-2028
6.5.3 Germany Aflibercept Biosimilars Market Size, 2017-2028
6.5.4 France Aflibercept Biosimilars Market Size, 2017-2028
6.5.5 U.K. Aflibercept Biosimilars Market Size, 2017-2028
6.5.6 Italy Aflibercept Biosimilars Market Size, 2017-2028
6.5.7 Russia Aflibercept Biosimilars Market Size, 2017-2028
6.5.8 Nordic Countries Aflibercept Biosimilars Market Size, 2017-2028
6.5.9 Benelux Aflibercept Biosimilars Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Aflibercept Biosimilars Revenue, 2017-2028
6.6.2 By Region - Asia Aflibercept Biosimilars Sales, 2017-2028
6.6.3 China Aflibercept Biosimilars Market Size, 2017-2028
6.6.4 Japan Aflibercept Biosimilars Market Size, 2017-2028
6.6.5 South Korea Aflibercept Biosimilars Market Size, 2017-2028
6.6.6 Southeast Asia Aflibercept Biosimilars Market Size, 2017-2028
6.6.7 India Aflibercept Biosimilars Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Aflibercept Biosimilars Revenue, 2017-2028
6.7.2 By Country - South America Aflibercept Biosimilars Sales, 2017-2028
6.7.3 Brazil Aflibercept Biosimilars Market Size, 2017-2028
6.7.4 Argentina Aflibercept Biosimilars Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Aflibercept Biosimilars Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Aflibercept Biosimilars Sales, 2017-2028
6.8.3 Turkey Aflibercept Biosimilars Market Size, 2017-2028
6.8.4 Israel Aflibercept Biosimilars Market Size, 2017-2028
6.8.5 Saudi Arabia Aflibercept Biosimilars Market Size, 2017-2028
6.8.6 UAE Aflibercept Biosimilars Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Regeneron
7.1.1 Regeneron Corporate Summary
7.1.2 Regeneron Business Overview
7.1.3 Regeneron Aflibercept Biosimilars Major Product Offerings
7.1.4 Regeneron Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.1.5 Regeneron Key News
7.2 Sanofi
7.2.1 Sanofi Corporate Summary
7.2.2 Sanofi Business Overview
7.2.3 Sanofi Aflibercept Biosimilars Major Product Offerings
7.2.4 Sanofi Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.2.5 Sanofi Key News
7.3 Novartis
7.3.1 Novartis Corporate Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Aflibercept Biosimilars Major Product Offerings
7.3.4 Novartis Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.3.5 Novartis Key News
7.4 Genentech
7.4.1 Genentech Corporate Summary
7.4.2 Genentech Business Overview
7.4.3 Genentech Aflibercept Biosimilars Major Product Offerings
7.4.4 Genentech Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.4.5 Genentech Key News
7.5 Roche
7.5.1 Roche Corporate Summary
7.5.2 Roche Business Overview
7.5.3 Roche Aflibercept Biosimilars Major Product Offerings
7.5.4 Roche Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.5.5 Roche Key News
7.6 Pfizer
7.6.1 Pfizer Corporate Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Aflibercept Biosimilars Major Product Offerings
7.6.4 Pfizer Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.6.5 Pfizer Key News
7.7 Sartorius
7.7.1 Sartorius Corporate Summary
7.7.2 Sartorius Business Overview
7.7.3 Sartorius Aflibercept Biosimilars Major Product Offerings
7.7.4 Sartorius Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.7.5 Sartorius Key News
7.8 Eli Lilly
7.8.1 Eli Lilly Corporate Summary
7.8.2 Eli Lilly Business Overview
7.8.3 Eli Lilly Aflibercept Biosimilars Major Product Offerings
7.8.4 Eli Lilly Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.8.5 Eli Lilly Key News
7.9 Bayer
7.9.1 Bayer Corporate Summary
7.9.2 Bayer Business Overview
7.9.3 Bayer Aflibercept Biosimilars Major Product Offerings
7.9.4 Bayer Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.9.5 Bayer Key News
7.10 Amgen
7.10.1 Amgen Corporate Summary
7.10.2 Amgen Business Overview
7.10.3 Amgen Aflibercept Biosimilars Major Product Offerings
7.10.4 Amgen Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.10.5 Amgen Key News
7.11 PlantForm
7.11.1 PlantForm Corporate Summary
7.11.2 PlantForm Aflibercept Biosimilars Business Overview
7.11.3 PlantForm Aflibercept Biosimilars Major Product Offerings
7.11.4 PlantForm Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.11.5 PlantForm Key News
7.12 PharmaPraxis
7.12.1 PharmaPraxis Corporate Summary
7.12.2 PharmaPraxis Aflibercept Biosimilars Business Overview
7.12.3 PharmaPraxis Aflibercept Biosimilars Major Product Offerings
7.12.4 PharmaPraxis Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.12.5 PharmaPraxis Key News
7.13 Samsung Bioepis
7.13.1 Samsung Bioepis Corporate Summary
7.13.2 Samsung Bioepis Aflibercept Biosimilars Business Overview
7.13.3 Samsung Bioepis Aflibercept Biosimilars Major Product Offerings
7.13.4 Samsung Bioepis Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.13.5 Samsung Bioepis Key News
7.14 Centus
7.14.1 Centus Corporate Summary
7.14.2 Centus Business Overview
7.14.3 Centus Aflibercept Biosimilars Major Product Offerings
7.14.4 Centus Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.14.5 Centus Key News
7.15 Cadila Pharmaceuticals
7.15.1 Cadila Pharmaceuticals Corporate Summary
7.15.2 Cadila Pharmaceuticals Business Overview
7.15.3 Cadila Pharmaceuticals Aflibercept Biosimilars Major Product Offerings
7.15.4 Cadila Pharmaceuticals Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.15.5 Cadila Pharmaceuticals Key News
7.16 Dr Reddy's
7.16.1 Dr Reddy's Corporate Summary
7.16.2 Dr Reddy's Business Overview
7.16.3 Dr Reddy's Aflibercept Biosimilars Major Product Offerings
7.16.4 Dr Reddy's Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.16.5 Dr Reddy's Key News
7.17 Aurobindo Pharma
7.17.1 Aurobindo Pharma Corporate Summary
7.17.2 Aurobindo Pharma Business Overview
7.17.3 Aurobindo Pharma Aflibercept Biosimilars Major Product Offerings
7.17.4 Aurobindo Pharma Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.17.5 Aurobindo Pharma Key News
7.18 Biocad
7.18.1 Biocad Corporate Summary
7.18.2 Biocad Business Overview
7.18.3 Biocad Aflibercept Biosimilars Major Product Offerings
7.18.4 Biocad Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.18.5 Biocad Key News
7.19 MAbxience
7.19.1 MAbxience Corporate Summary
7.19.2 MAbxience Business Overview
7.19.3 MAbxience Aflibercept Biosimilars Major Product Offerings
7.19.4 MAbxience Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.19.5 MAbxience Key News
7.20 Hetero
7.20.1 Hetero Corporate Summary
7.20.2 Hetero Business Overview
7.20.3 Hetero Aflibercept Biosimilars Major Product Offerings
7.20.4 Hetero Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.20.5 Hetero Key News
7.21 Biocon
7.21.1 Biocon Corporate Summary
7.21.2 Biocon Business Overview
7.21.3 Biocon Aflibercept Biosimilars Major Product Offerings
7.21.4 Biocon Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.21.5 Biocon Key News
7.22 Kirin Biologics
7.22.1 Kirin Biologics Corporate Summary
7.22.2 Kirin Biologics Business Overview
7.22.3 Kirin Biologics Aflibercept Biosimilars Major Product Offerings
7.22.4 Kirin Biologics Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.22.5 Kirin Biologics Key News
7.23 Mylan
7.23.1 Mylan Corporate Summary
7.23.2 Mylan Business Overview
7.23.3 Mylan Aflibercept Biosimilars Major Product Offerings
7.23.4 Mylan Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.23.5 Mylan Key News
7.24 BeiGene
7.24.1 BeiGene Corporate Summary
7.24.2 BeiGene Business Overview
7.24.3 BeiGene Aflibercept Biosimilars Major Product Offerings
7.24.4 BeiGene Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.24.5 BeiGene Key News
7.25 Innovent
7.25.1 Innovent Corporate Summary
7.25.2 Innovent Business Overview
7.25.3 Innovent Aflibercept Biosimilars Major Product Offerings
7.25.4 Innovent Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.25.5 Innovent Key News
7.26 Qilu Pharmaceutical
7.26.1 Qilu Pharmaceutical Corporate Summary
7.26.2 Qilu Pharmaceutical Business Overview
7.26.3 Qilu Pharmaceutical Aflibercept Biosimilars Major Product Offerings
7.26.4 Qilu Pharmaceutical Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.26.5 Qilu Pharmaceutical Key News
7.27 Hengrui Pharmaceuticals
7.27.1 Hengrui Pharmaceuticals Corporate Summary
7.27.2 Hengrui Pharmaceuticals Business Overview
7.27.3 Hengrui Pharmaceuticals Aflibercept Biosimilars Major Product Offerings
7.27.4 Hengrui Pharmaceuticals Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.27.5 Hengrui Pharmaceuticals Key News
7.28 Hisun Pharmaceutical
7.28.1 Hisun Pharmaceutical Corporate Summary
7.28.2 Hisun Pharmaceutical Business Overview
7.28.3 Hisun Pharmaceutical Aflibercept Biosimilars Major Product Offerings
7.28.4 Hisun Pharmaceutical Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.28.5 Hisun Pharmaceutical Key News
7.29 TOT BIOPHARM
7.29.1 TOT BIOPHARM Corporate Summary
7.29.2 TOT BIOPHARM Business Overview
7.29.3 TOT BIOPHARM Aflibercept Biosimilars Major Product Offerings
7.29.4 TOT BIOPHARM Aflibercept Biosimilars Sales and Revenue in Global (2017-2022)
7.29.5 TOT BIOPHARM Key News
8 Global Aflibercept Biosimilars Production Capacity, Analysis
8.1 Global Aflibercept Biosimilars Production Capacity, 2017-2028
8.2 Aflibercept Biosimilars Production Capacity of Key Manufacturers in Global Market
8.3 Global Aflibercept Biosimilars Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Aflibercept Biosimilars Supply Chain Analysis
10.1 Aflibercept Biosimilars Industry Value Chain
10.2 Aflibercept Biosimilars Upstream Market
10.3 Aflibercept Biosimilars Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Aflibercept Biosimilars Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. Key Players of Aflibercept Biosimilars in Global Market
Table 2. Top Aflibercept Biosimilars Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Aflibercept Biosimilars Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Aflibercept Biosimilars Revenue Share by Companies, 2017-2022
Table 5. Global Aflibercept Biosimilars Sales by Companies, (K Units), 2017-2022
Table 6. Global Aflibercept Biosimilars Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Aflibercept Biosimilars Price (2017-2022) & (K USD/Unit)
Table 8. Global Manufacturers Aflibercept Biosimilars Product Type
Table 9. List of Global Tier 1 Aflibercept Biosimilars Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Aflibercept Biosimilars Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Aflibercept Biosimilars Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Aflibercept Biosimilars Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Aflibercept Biosimilars Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Aflibercept Biosimilars Sales (K Units), 2017-2022
Table 15. By Type - Global Aflibercept Biosimilars Sales (K Units), 2023-2028
Table 16. By Application ? Global Aflibercept Biosimilars Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Aflibercept Biosimilars Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Aflibercept Biosimilars Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Aflibercept Biosimilars Sales (K Units), 2017-2022
Table 20. By Application - Global Aflibercept Biosimilars Sales (K Units), 2023-2028
Table 21. By Region ? Global Aflibercept Biosimilars Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Aflibercept Biosimilars Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Aflibercept Biosimilars Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Aflibercept Biosimilars Sales (K Units), 2017-2022
Table 25. By Region - Global Aflibercept Biosimilars Sales (K Units), 2023-2028
Table 26. By Country - North America Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Aflibercept Biosimilars Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Aflibercept Biosimilars Sales, (K Units), 2017-2022
Table 29. By Country - North America Aflibercept Biosimilars Sales, (K Units), 2023-2028
Table 30. By Country - Europe Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Aflibercept Biosimilars Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Aflibercept Biosimilars Sales, (K Units), 2017-2022
Table 33. By Country - Europe Aflibercept Biosimilars Sales, (K Units), 2023-2028
Table 34. By Region - Asia Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Aflibercept Biosimilars Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Aflibercept Biosimilars Sales, (K Units), 2017-2022
Table 37. By Region - Asia Aflibercept Biosimilars Sales, (K Units), 2023-2028
Table 38. By Country - South America Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Aflibercept Biosimilars Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Aflibercept Biosimilars Sales, (K Units), 2017-2022
Table 41. By Country - South America Aflibercept Biosimilars Sales, (K Units), 2023-2028
Table 42. By Country - Middle East & Africa Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Aflibercept Biosimilars Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Aflibercept Biosimilars Sales, (K Units), 2017-2022
Table 45. By Country - Middle East & Africa Aflibercept Biosimilars Sales, (K Units), 2023-2028
Table 46. Regeneron Corporate Summary
Table 47. Regeneron Aflibercept Biosimilars Product Offerings
Table 48. Regeneron Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 49. Sanofi Corporate Summary
Table 50. Sanofi Aflibercept Biosimilars Product Offerings
Table 51. Sanofi Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 52. Novartis Corporate Summary
Table 53. Novartis Aflibercept Biosimilars Product Offerings
Table 54. Novartis Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 55. Genentech Corporate Summary
Table 56. Genentech Aflibercept Biosimilars Product Offerings
Table 57. Genentech Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 58. Roche Corporate Summary
Table 59. Roche Aflibercept Biosimilars Product Offerings
Table 60. Roche Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 61. Pfizer Corporate Summary
Table 62. Pfizer Aflibercept Biosimilars Product Offerings
Table 63. Pfizer Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 64. Sartorius Corporate Summary
Table 65. Sartorius Aflibercept Biosimilars Product Offerings
Table 66. Sartorius Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 67. Eli Lilly Corporate Summary
Table 68. Eli Lilly Aflibercept Biosimilars Product Offerings
Table 69. Eli Lilly Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 70. Bayer Corporate Summary
Table 71. Bayer Aflibercept Biosimilars Product Offerings
Table 72. Bayer Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 73. Amgen Corporate Summary
Table 74. Amgen Aflibercept Biosimilars Product Offerings
Table 75. Amgen Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 76. PlantForm Corporate Summary
Table 77. PlantForm Aflibercept Biosimilars Product Offerings
Table 78. PlantForm Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 79. PharmaPraxis Corporate Summary
Table 80. PharmaPraxis Aflibercept Biosimilars Product Offerings
Table 81. PharmaPraxis Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 82. Samsung Bioepis Corporate Summary
Table 83. Samsung Bioepis Aflibercept Biosimilars Product Offerings
Table 84. Samsung Bioepis Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 85. Centus Corporate Summary
Table 86. Centus Aflibercept Biosimilars Product Offerings
Table 87. Centus Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 88. Cadila Pharmaceuticals Corporate Summary
Table 89. Cadila Pharmaceuticals Aflibercept Biosimilars Product Offerings
Table 90. Cadila Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 91. Dr Reddy's Corporate Summary
Table 92. Dr Reddy's Aflibercept Biosimilars Product Offerings
Table 93. Dr Reddy's Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 94. Aurobindo Pharma Corporate Summary
Table 95. Aurobindo Pharma Aflibercept Biosimilars Product Offerings
Table 96. Aurobindo Pharma Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 97. Biocad Corporate Summary
Table 98. Biocad Aflibercept Biosimilars Product Offerings
Table 99. Biocad Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 100. MAbxience Corporate Summary
Table 101. MAbxience Aflibercept Biosimilars Product Offerings
Table 102. MAbxience Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 103. Hetero Corporate Summary
Table 104. Hetero Aflibercept Biosimilars Product Offerings
Table 105. Hetero Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 106. Biocon Corporate Summary
Table 107. Biocon Aflibercept Biosimilars Product Offerings
Table 108. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 109. Kirin Biologics Corporate Summary
Table 110. Kirin Biologics Aflibercept Biosimilars Product Offerings
Table 111. Kirin Biologics Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 112. Mylan Corporate Summary
Table 113. Mylan Aflibercept Biosimilars Product Offerings
Table 114. Mylan Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 115. BeiGene Corporate Summary
Table 116. BeiGene Aflibercept Biosimilars Product Offerings
Table 117. BeiGene Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 118. Innovent Corporate Summary
Table 119. Innovent Aflibercept Biosimilars Product Offerings
Table 120. Innovent Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 121. Qilu Pharmaceutical Corporate Summary
Table 122. Qilu Pharmaceutical Aflibercept Biosimilars Product Offerings
Table 123. Qilu Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 124. Hengrui Pharmaceuticals Corporate Summary
Table 125. Hengrui Pharmaceuticals Aflibercept Biosimilars Product Offerings
Table 126. Hengrui Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 127. Hisun Pharmaceutical Corporate Summary
Table 128. Hisun Pharmaceutical Aflibercept Biosimilars Product Offerings
Table 129. Hisun Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 130. TOT BIOPHARM Corporate Summary
Table 131. TOT BIOPHARM Aflibercept Biosimilars Product Offerings
Table 132. TOT BIOPHARM Aflibercept Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (K USD/Unit) (2017-2022)
Table 133. Aflibercept Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
Table 134. Global Aflibercept Biosimilars Capacity Market Share of Key Manufacturers, 2020-2022
Table 135. Global Aflibercept Biosimilars Production by Region, 2017-2022 (K Units)
Table 136. Global Aflibercept Biosimilars Production by Region, 2023-2028 (K Units)
Table 137. Aflibercept Biosimilars Market Opportunities & Trends in Global Market
Table 138. Aflibercept Biosimilars Market Drivers in Global Market
Table 139. Aflibercept Biosimilars Market Restraints in Global Market
Table 140. Aflibercept Biosimilars Raw Materials
Table 141. Aflibercept Biosimilars Raw Materials Suppliers in Global Market
Table 142. Typical Aflibercept Biosimilars Downstream
Table 143. Aflibercept Biosimilars Downstream Clients in Global Market
Table 144. Aflibercept Biosimilars Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Aflibercept Biosimilars Segment by Type
Figure 2. Aflibercept Biosimilars Segment by Application
Figure 3. Global Aflibercept Biosimilars Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Aflibercept Biosimilars Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Aflibercept Biosimilars Revenue, 2017-2028 (US$, Mn)
Figure 7. Aflibercept Biosimilars Sales in Global Market: 2017-2028 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Aflibercept Biosimilars Revenue in 2021
Figure 9. By Type - Global Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 10. By Type - Global Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 11. By Type - Global Aflibercept Biosimilars Price (K USD/Unit), 2017-2028
Figure 12. By Application - Global Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 13. By Application - Global Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 14. By Application - Global Aflibercept Biosimilars Price (K USD/Unit), 2017-2028
Figure 15. By Region - Global Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 16. By Region - Global Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 17. By Country - North America Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 18. By Country - North America Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 19. US Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 24. Germany Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 25. France Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 33. China Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 37. India Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 39. By Country - South America Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 40. Brazil Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Aflibercept Biosimilars Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Aflibercept Biosimilars Sales Market Share, 2017-2028
Figure 44. Turkey Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Aflibercept Biosimilars Revenue, (US$, Mn), 2017-2028
Figure 48. Global Aflibercept Biosimilars Production Capacity (K Units), 2017-2028
Figure 49. The Percentage of Production Aflibercept Biosimilars by Region, 2021 VS 2028
Figure 50. Aflibercept Biosimilars Industry Value Chain
Figure 51. Marketing Channels

REPORT PURCHASE OPTIONS

USD Single User Price
USD Multi User Price
USD Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount